Hanmi Licenses Muscle-Preserving Obesity Candidate to Genentech for Up to $2.3 Billion
Hanmi Pharmaceutical has handed Genentech, the U.S. biotech arm of Roche, exclusive worldwide rights outside Korea to HM17321, an obesity and metabolic-disease candidate designed to help patients shed fat without losing muscle. The deal, disclosed on August 24, is worth up to $2.3 billion — roughly 3.2 trillion won — and delivers Hanmi an upfront payment of $190 million, or about 285 billion won, regardless of how the program ultimately fares.
Terms of the Agreement
Under the exclusive license, Genentech takes over development, manufacturing, and commercialization of HM17321 everywhere except Korea, where Hanmi retains its position. The $190 million upfront is the guaranteed portion; the remainder of the headline figure is contingent on the candidate clearing development, regulatory, and commercial milestones on its way to market.
The structure is a familiar one for Korean pharmaceutical licensing, where headline values routinely dwarf the cash that changes hands at signing. Even so, an upfront payment approaching $200 million puts this transaction among the larger out-licensing deals struck by a Korean drugmaker, and the counterparty matters as much as the number: Genentech brings the development infrastructure and commercial reach of the Roche group to a molecule that has not yet completed clinical development.
A Different Bet in a Crowded Obesity Market
HM17321, also identified as LA-UCN2, is positioned around a specific weakness of the current generation of weight-loss drugs. GLP-1-based therapies have transformed obesity treatment, but a meaningful share of the weight patients lose on them is lean mass rather than fat. A candidate that preserves — or builds — muscle while driving fat loss addresses the most commonly cited limitation of the incumbents, whether used on its own or alongside existing therapies.
That is the thesis Genentech is paying to test. The designation LA-UCN2 points to a long-acting form of urocortin-2, a peptide that acts through a different receptor pathway than the GLP-1 class, which would place the program in the wave of next-generation obesity assets aimed at improving body composition rather than simply lowering the number on the scale. Hanmi is also developing the candidate with type 2 diabetes and other metabolic conditions in view, broadening the potential label beyond weight loss alone.
What It Means for Hanmi
For Hanmi, the agreement converts an early-stage asset into immediate capital and a validation stamp from one of the industry’s most selective licensees, while keeping the Korean market in its own hands. The company has been rebuilding its licensing track record after high-profile deals in the past decade were returned by partners, and a Roche-group endorsement of its metabolic-disease pipeline strengthens its case as a repeatable originator of globally competitive candidates rather than a one-off dealmaker.
The risks run in the usual direction. Milestone-heavy deals pay out only if the science holds up through years of clinical trials, and the obesity field is unforgiving: well-funded programs from far larger companies have already been shelved after underwhelming data. The next markers worth tracking are the clinical timeline Genentech sets for HM17321 and the first human efficacy data on the muscle-preservation claim — the property that made this molecule worth up to $2.3 billion to one of the most discriminating buyers in the industry.